Related Experiment Video
Updated: Jun 22, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
Published on: February 8, 2019
Treatment and outcomes of large vessel arteritis
Frances A Borg1, Bhaskar Dasgupta
1Department of Rheumatology, Southend University Hospital, Essex, UK.
Insights
Giant cell arteritis (GCA) and Takayasu's arteritis (TA) are inflammatory diseases affecting large arteries. Early recognition and treatment are crucial to prevent vision loss and other complications.
Area of Science:
- Rheumatology
- Internal Medicine
- Vascular Medicine
Background:
- Giant cell arteritis (GCA) and Takayasu's arteritis (TA) are systemic inflammatory conditions affecting large arteries.
- These conditions can lead to critical ischemia and significant morbidity, including permanent vision loss in GCA.
- Delayed diagnosis, often due to non-specific early symptoms and discordant inflammatory markers, complicates management.
Purpose of the Study:
- To review the current understanding and management of large vessel vasculitis, focusing on GCA and TA.
- To highlight the challenges in early diagnosis and the role of modern imaging techniques.
- To discuss current and potential future therapeutic strategies.
Main Methods:
- Literature review of large vessel vasculitis, focusing on diagnosis and treatment.
- Analysis of clinical presentation, diagnostic challenges, and therapeutic outcomes.
- Evaluation of the role of imaging and novel therapies.
Main Results:
- GCA is a medical emergency with high risk of early neuro-ophthalmic complications, including vision loss.
- Diagnosis of large vessel vasculitis is frequently delayed.
- Corticosteroids remain the primary treatment, with mixed results for conventional DMARDs and ongoing evaluation of biologics.
Conclusions:
- Prompt recognition and treatment of GCA are essential to prevent irreversible vision loss.
- Improved diagnostic strategies, including advanced imaging, are needed.
- Further research into steroid-sparing therapies, including biologics, is required for effective long-term management of large vessel vasculitis.
Abstract:
Giant cell arteritis (GCA) and Takayasu's arteritis (TA) are characterised by systemic inflammation and critical ischaemia. GCA is a medical emergency. Neuro-ophthalmic complications occur early, with permanent vision loss in up to a fifth of patients, resulting mainly from failure of prompt recognition and treatment. Diagnosis of large vessel vasculitis is often delayed due to poor recognition of early, often non-specific symptoms. Laboratory inflammatory markers are often discordant with disease activity. Modern imaging techniques show promise in diagnosis and disease monitoring, improving our understanding of major artery involvement in large vessel vasculitis. However, in practice, their role is still unclear. The mainstay of therapy remains corticosteroids. Experience using conventional disease-modifying drugs is mixed, and biological therapies require further evaluation for their steroid-sparing potential.
Related Concept Videos
Atherosclerosis III: Management
Peripheral Artery Disease III: Interprofessional Care
Aneurysm III: Interprofessional Care
Atherosclerosis IV: Nursing Management
Aortic Regurgitation III: Medical Management
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
